Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
Ractopamine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ractopamine
- Accession Number
- DB11541
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
Structure for Ractopamine (DB11541)
- Weight
- Average: 301.386
Monoisotopic: 301.167793605 - Chemical Formula
- C18H23NO3
- Synonyms
- Not Available
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UEstrogen receptor alpha Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcebutolol The therapeutic efficacy of Ractopamine can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Ractopamine. Acemetacin The risk or severity of hypertension can be increased when Ractopamine is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ractopamine. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Ractopamine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Ractopamine. Alclofenac The risk or severity of hypertension can be increased when Ractopamine is combined with Alclofenac. Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Ractopamine. Alfuzosin The therapeutic efficacy of Ractopamine can be decreased when used in combination with Alfuzosin. Aliskiren Ractopamine may decrease the antihypertensive activities of Aliskiren. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Ractopamine hydrochloride 309G9J93TP 90274-24-1 JHGSLSLUFMZUMK-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids. These are phenols that a unsubstituted at the 2-position.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenols
- Sub Class
- 1-hydroxy-2-unsubstituted benzenoids
- Direct Parent
- 1-hydroxy-2-unsubstituted benzenoids
- Alternative Parents
- Aralkylamines / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- secondary alcohol, benzyl alcohols, secondary amino compound, polyphenol (CHEBI:82647)
Chemical Identifiers
- UNII
- 57370OZ3P1
- CAS number
- Not Available
- InChI Key
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H23NO3/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15/h4-11,13,18-22H,2-3,12H2,1H3
- IUPAC Name
- 4-(3-{[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino}butyl)phenol
- SMILES
- CC(CCC1=CC=C(O)C=C1)NCC(O)C1=CC=C(O)C=C1
References
- General References
- Smith DJ, Shelver WL: Tissue residues of ractopamine and urinary excretion of ractopamine and metabolites in animals treated for 7 days with dietary ractopamine. J Anim Sci. 2002 May;80(5):1240-9. [PubMed:12019611]
- Chen XA, Huang PJ, Hou DB, Kang XS, Zhang GX, Zhou ZK: [Terahertz time-domain spectroscopy of ractopamine hydrochloride]. Guang Pu Xue Yu Guang Pu Fen Xi. 2011 Mar;31(3):600-3. [PubMed:21595199]
- Adeola O, Darko EA, He P, Young LG: Manipulation of porcine carcass composition by ractopamine. J Anim Sci. 1990 Nov;68(11):3633-41. [PubMed:1979784]
- Athayde NB, Dalla Costa OA, Roca RO, Guidoni AL, Ludtke CB, Oba E, Takahira RK, Lima GJ: Stress susceptibility in pigs supplemented with ractopamine. J Anim Sci. 2013 Sep;91(9):4180-7. doi: 10.2527/jas.2011-5014. Epub 2013 Jul 3. [PubMed:23825348]
- Scramlin SM, Carr SN, Parks CW, Fernandez-Duenas DM, Leick CM, McKeith FK, Killefer J: Effect of ractopamine level, gender, and duration of ractopamine on belly and bacon quality traits. Meat Sci. 2008 Dec;80(4):1218-21. doi: 10.1016/j.meatsci.2008.05.034. Epub 2008 Jun 3. [PubMed:22063860]
- Smith DJ, Giddings JM, Feil VJ, Paulson GD: Identification of ractopamine hydrochloride metabolites excreted in rat bile. Xenobiotica. 1995 May;25(5):511-20. [PubMed:7571724]
- Yen JT, Mersmann HJ, Hill DA, Pond WG: Effects of ractopamine on genetically obese and lean pigs. J Anim Sci. 1990 Nov;68(11):3705-12. [PubMed:1979785]
- Bergen WG, Johnson SE, Skjaerlund DM, Babiker AS, Ames NK, Merkel RA, Anderson DB: Muscle protein metabolism in finishing pigs fed ractopamine. J Anim Sci. 1989 Sep;67(9):2255-62. [PubMed:2480945]
- Mills SE, Kissel J, Bidwell CA, Smith DJ: Stereoselectivity of porcine beta-adrenergic receptors for ractopamine stereoisomers. J Anim Sci. 2003 Jan;81(1):122-9. [PubMed:12597381]
- Wang Z, Liu M, Shi W, Li C, Zhang S, Shen J: New haptens and antibodies for ractopamine. Food Chem. 2015 Sep 15;183:111-4. doi: 10.1016/j.foodchem.2015.03.043. Epub 2015 Mar 19. [PubMed:25863617]
- External Links
- ChemSpider
- 50604
- BindingDB
- 27959
- 1311677
- ChEBI
- 82647
- ChEMBL
- CHEMBL509336
- Wikipedia
- Ractopamine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0266 mg/mL ALOGPS logP 2.17 ALOGPS logP 2.2 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 9.19 ChemAxon pKa (Strongest Basic) 9.89 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 72.72 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 87.62 m3·mol-1 ChemAxon Polarizability 33.58 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-08ni-0910000000-c514f20dba03cf651500
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Curator comments
- Weak activator
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- McRobb FM, Kufareva I, Abagyan R: In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor alpha. Toxicol Sci. 2014 Sep;141(1):188-97. doi: 10.1093/toxsci/kfu114. Epub 2014 Jun 13. [PubMed:24928891]
Drug created on February 26, 2016 10:40 / Updated on June 12, 2020 10:53
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg","ThriveHealth-1.jpg":"/assets/ads/ThriveHealth-1-fe42678c71bf2ec7d508fde77efbe9f0aa868c5fa03bd39a7e1c97cefac0fa9d.jpg","ThriveHealth-2.jpg":"/assets/ads/ThriveHealth-2-32bb14bb00de8a1b2efc2a51ce37f490c01e76dac7b9c09b6b831c50640b6567.jpg","ThriveHealth-3.jpg":"/assets/ads/ThriveHealth-3-e184eae1745f8aa22525b294b761ee89f5a854a434d50e5d6d37c0b77f2cf523.jpg","ThriveHealth-4.jpg":"/assets/ads/ThriveHealth-4-218f710e6d20831711d0920e585b986217c38f38d9849b8dd32bb56f68d2eea9.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates